1-11 of 11
Robert J. Fram
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Pevonedistat (PEV) + Azacitidine (AZA) Versus AZA Alone As First-Line Treatment for Patients with Higher-Risk Myelodysplastic Syndromes (MDS)/Chronic Myelomonocytic Leukemia (CMML) or Acute Myeloid Leukemia (AML) with 20-30% Marrow Blasts: The Randomized Phase 3 PANTHER Trial (NCT03268954)

Mikkael A. Sekeres, Larisa Girshova, Vadim A Doronin, Maria Diez-Campelo, David Valcarcel, Suman Kambhampati, Nora-Athina Viniou, Dariusz Woszczyk, Raquel De Paz Arias, Argiris Symeonidis, Achilles Anagnostopoulos, Eduardo Ciliao Munhoz, Uwe Platzbecker, Valeria Santini, Robert J. Fram, Ying Yuan, Douglas V. Faller, Lionel Ades
Journal: Blood
Blood (2021) 138 (Supplement 1): 242.
https://doi.org/10.1182/blood-2021-146154
Published: 2021
Journal Articles

Randomized Phase 2 Trial of Pevonedistat Plus Azacitidine Versus Azacitidine in Higher-Risk Myelodysplastic Syndromes/Chronic Myelomonocytic Leukemia or Low-Blast Acute Myeloid Leukemia: Exploratory Analysis of Patient-Reported Outcomes

Joshua F. Zeidner, MD, Flora Mazerolle, MSc, Jill A. Bell, PhD MS, Lauren E. Cain, MHS, ScM, PhD, Douglas V. Faller, Mehul Dalal, PhD, Antoine Regnault, PhD, Robert J. Fram
Journal: Blood
Blood (2020) 136 (Supplement 1): 39–40.
https://doi.org/10.1182/blood-2020-136935
Published: 2020
Journal Articles

DNA Methylation Analysis before and during Treatment with Azacitidine Plus Pevonedistat or Azacitidine Alone in Patients with MDS, CMML, and AML Previously Untreated with Hypomethylating Agents

Soo Park, MD, Brian M Reilly, BS, Timothy Luger, Dan Zhao, Robert J. Fram, MD, Ajeeta B Dash, PhD, Rafael Bejar, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 29–30.
https://doi.org/10.1182/blood-2020-134484
Published: 2020
Journal Articles

Patient-Centered Evaluation of Clinical Benefit in Acute Myeloid Leukemia: Importance of Early Engagement with Patients

Jill A. Bell, PhD MS, Farrah Anne Pompilus, MA, Alissa Rams, BA, Yanyan Zhu, PhD MPH, Anna Ciesluk, MPH, Rafael Bejar, MD PhD, Robert J. Fram, MD, Douglas V. Faller, MD PhD, Patrick Marquis, MD MBA
Journal: Blood
Blood (2019) 134 (Supplement_1): 5898.
https://doi.org/10.1182/blood-2019-128517
Published: 2019
Journal Articles

Assessing Patient-Reported Outcomes in People with Myelodysplastic Syndromes: Can a Customized Selection of Items from the EORTC Library Enhance the EORTC QLQ-C30?

Jill A Bell, PhD, Farrah A Pompilus, Anna Christian, MPH, Flora Mazerolle, MSc, Fatima Scipione, Rafael Bejar, MD PhD, Aaron Galaznik, PhD, Robert J. Fram, MD, Douglas V. Faller, MD PhD, Stefan Cano, PhD CPsychol, AFBPsS, Antoine Regnault, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 4856.
https://doi.org/10.1182/blood-2018-99-116977
Published: 2018
Journal Articles

Enhancing the Content of the EORTC QLQ-C30 to Maximize the Detection of Treatment Benefit in Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, and Low-Blast Acute Myeloid Leukemia Using the EORTC Item Bank

Jill A Bell, PhD, Aaron Galaznik, MD, Farrah A Pompilus, Sara Strzok, Rafael Bejar, MD PhD, Robert J. Fram, MD, Douglas V. Faller, MD PhD, Patrick Marquis
Journal: Blood
Blood (2017) 130 (Supplement 1): 3457.
https://doi.org/10.1182/blood.V130.Suppl_1.3457.3457
Published: 2017
Journal Articles

Patient Perspectives on Symptom Experience and Impact on Health-Related Quality of Life in Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia and Low-Blast Acute Myeloid Leukemia

Jill A Bell, PhD, Aaron Galaznik, MD, Farrah A Pompilus, Sara Strzok, Robert J. Fram, MD, Douglas V. Faller, MD PhD, Patrick Marquis
Journal: Blood
Blood (2017) 130 (Supplement 1): 3458.
https://doi.org/10.1182/blood.V130.Suppl_1.3458.3458
Published: 2017
Journal Articles

Healthcare Costs in Elderly Patients with Acute Myeloid Leukemia (AML) in Routine Clinical Care in the United States (US)

Jill A Bell, PhD, Aaron Galaznik, MD, Sharanya Murty, PhD, Megan Pollack, PharmD, Augustina Ogbonnaya, MPH, Michael T. Eaddy, PharmD, PhD, Robert J. Fram, MD, Douglas V. Faller, MD PhD, Vamsi Kota, MBBS
Journal: Blood
Blood (2017) 130 (Supplement 1): 3459.
https://doi.org/10.1182/blood.V130.Suppl_1.3459.3459
Published: 2017
Journal Articles

Treatment Characteristics and Outcomes for Newly Diagnosed Elderly Patients with Acute Myeloid Leukemia (AML) Treated in the United States with Either 7+3 or a Hypomethylating Agent (HMA)

Jill A Bell, PhD, Aaron Galaznik, MD, Eileen Farrelly, MPH, Sharanya Murty, PhD, Augustina Ogbonnaya, MPH, Michael T. Eaddy, PharmD, PhD, Robert J. Fram, MD, Douglas V. Faller, MD PhD, Vamsi Kota, MBBS
Journal: Blood
Blood (2017) 130 (Supplement 1): 2167.
https://doi.org/10.1182/blood.V130.Suppl_1.2167.2167
Published: 2017
Journal Articles

Phase I Study of huN901-DM1 (BB-10901) in Patients with Relapsed and Relapsed/Refractory CD56-Positive Multiple Myeloma.

Asher A. Chanan-Khan, MD, Sundar Jagannath, MD, Nikhil C. Munshi, MD, Robert L. Schlossman, MD, Kenneth C. Anderson, MD, Kelvin Lee, MD, Dawn DePaolo, Kena C. Miller, NP, Sybil Zildjian, Robert J. Fram, MD, Qin
Journal: Blood
Blood (2007) 110 (11): 1174.
https://doi.org/10.1182/blood.V110.11.1174.1174
Published: 2007
Journal Articles

Phase I Study of BB-10901 (huN901-DM1) in Patients with Relapsed and Relapsed/Refractory CD56-Positive Multiple Myeloma.

Asher Alban Chanan-Khan, MD, Sundar Jagannath, MD, Robert L. Schlossman, MD, Robert J. Fram, MD, Richard M. Falzone, Mary F. Ruberti, Samantha K. Welch, Dawn DePaolo, Kenneth C. Anderson, MD, Nikhil C. Munshi, MD
Journal: Blood
Blood (2006) 108 (11): 3574.
https://doi.org/10.1182/blood.V108.11.3574.3574
Published: 2006